The 5th ALS Drug Development Summit returns to Boston as the ultimate platform honing industry R&D for safer, more effect and patient-relevant drugs that serve the community, driving a cure for sporadic and familial ALS.

With a brand-new agenda spanning early target exploration through to clinical design, biomarker strategy, and regulatory engagement, attendees will gain comprehensive insights into genetically validated targets, the evolving biology of TDP 43, adaptive trial design, and embedding the patient voice throughout development.

Join us for 3 days of unmissable data-driven content, with 2 tracks spanning discovery to access for the whole team:

Track A: Discovery, Preclinical & Translational – designed for CSOs, pre-clinical researchers, discovery scientists, directors of biology and research, novel modality scientists, in viva/in vitro modelling experts and many more, connect with an intimate group of discovery and preclinical experts for a more discursive session.

Track B: Clinical & Regulatory – tailor-made for medical directors, CMOs, clinical program leaders, translational and clinical development heads and clinicians and more; share expertise from diverse clinical challenges and innovation in ALS.

Designed for biotech, pharma, academia, and patient advocacy stakeholders, this unique forum will unite 100+ senior experts and 30+ speakers from companies including AbbVie, Biogen, Novartis, Eli Lilly, QurAlis, Prilenia, Sanofi, and many more.

Discover the full 2026 event guide now to explore all speakers and sessions – https://ter.li/28a6lw